Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Policy / Regulatory

China’s CDE Tightens Drug Review Standards with New “No Supplemental Data” Rule for Major Deficiencies

Fineline Cube Jul 29, 2026
Company Drug

Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval

Fineline Cube Jul 30, 2026
Company Drug

Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes

Fineline Cube Jul 29, 2026
Company Drug

Kira Pharmaceuticals Gains NMPA Approval for Phase II Study of KP104 in PNH

Fineline Cube Oct 17, 2022

Sino-US biotech Kira Pharmaceuticals has announced receiving approval from the National Medical Products Administration (NMPA)...

Company Drug

RemeGen’s Telitacicept Gains EU, China Approvals for Global Phase III Study

Fineline Cube Oct 17, 2022

China-based pharma firm RemeGen (HKG: 9995) has announced receiving approvals from authorities in the European...

Company Drug

Zelgen’s Jacktinib Shows Strong Efficacy in Phase III Myelofibrosis Study

Fineline Cube Oct 17, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has published major data from a Phase III...

Company Deals

Ningbo Menovo to Sell Zhejiang Liaoyuan Pharma Stake to Jemincare for RMB 512.58M

Fineline Cube Oct 17, 2022

China-based Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has announced plans to transfer all of...

Company Deals

Ausper Biopharma Raises USD 16M for HBV Drug and Vaccine Development

Fineline Cube Oct 14, 2022

Ausper Biopharma, Inc, a developer of drugs and vaccines for chronic hepatitis B virus (HBV)...

Company Deals

Alioth Biotech Raises RMB 100M in Series A Financing for Pharma Processing Products

Fineline Cube Oct 14, 2022

China-based Alioth Biotech (Shanghai) Co., Ltd has raised close to RMB 100 million (USD 13.9...

Company Deals

HICOMP MicroTech Raises RMB 100M in Series B+ Financing for Microfluidics Expansion

Fineline Cube Oct 14, 2022

China-based micro/nano technology developer HICOMP MicroTech (Suzhou) Co., Ltd has raised RMB 100 million (USD...

Company Drug

Kintor’s Dual c-Myc/GSPT1 Degradation Therapy GT19715 Shows Promise in Pre-Clinical Studies

Fineline Cube Oct 14, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has published positive results from a pre-clinical study of...

Company Drug

CARsgen’s BCMA-Targeted CAR-T Therapy CT053 Gains Priority Review in China

Fineline Cube Oct 14, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based chimeric antigen receptor (CAR)-T cell...

Company Drug

LianBio Cancels Phase III Trial for Truseltiq in China Amid Global Halt

Fineline Cube Oct 14, 2022

China-based LianBio (OTCMKTS: LIANY) revealed in an SEC filing that it is canceling work on...

Company Drug

Accutar Biotechnology Initiates Phase I Trial for ERα Targeting Degradation Molecule AC0682

Fineline Cube Oct 14, 2022

New Jersey-based Accutar Biotechnology Inc., which is heavily backed by Chinese funds, has announced the...

Policy / Regulatory R&D

CDE Releases Draft Guidelines for Extrapolating Adult Drug Data to Pediatric Use

Fineline Cube Oct 14, 2022

The Center for Drug Evaluation (CDE) has released the “Guidelines on Quantitative Methodology for Extrapolating...

Company Drug

RemeGen’s Telitacicept Receives FDA Orphan Drug Designation for Myasthenia Gravis

Fineline Cube Oct 13, 2022

China-based pharma firm RemeGen (HKG: 9995, SHA: 688331) has announced receiving Orphan Drug Designation (ODD)...

Company Deals

Jacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study

Fineline Cube Oct 13, 2022

China-based Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has announced a clinical study collaboration partnership...

Company Medical Device

Hotgen Biotech Gains Regulatory Approvals in Saudi Arabia and India

Fineline Cube Oct 13, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced receiving one certificate from the Saudi...

Company Drug

BeiGene’s Brukinsa Outperforms Imbruvica in Phase III ALPINE Study

Fineline Cube Oct 13, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that its Bruton’s...

Company

Hengrui Medicine’s Deputy GM Tao Weikang Resigns, Joins Qilu Pharma

Fineline Cube Oct 13, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its deputy general manager...

Company Deals

Proxinse Medtech Raises Series A Funding for Endoscope Camera System

Fineline Cube Oct 13, 2022

Shenzhen Proxinse Medical Technology Co., Ltd, a provider of minimally invasive surgery endoscope camera systems...

Company Deals

AlphaLife Sciences Raises Series A+ Funding for Clinical Research SaaS

Fineline Cube Oct 13, 2022

China-based clinical research SaaS service provider AlphaLife Sciences has reportedly raised “tens of millions” of...

Company Drug

Aosaikang’s Neratinib Maleate API Market Filing Accepted by NMPA

Fineline Cube Oct 13, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that the market filing for its...

Posts pagination

1 … 650 651 652 … 701

Recent updates

  • Xgene Pharmaceutical Secures $35M Series D Funding to Advance Non-Opioid Pain Therapy XG005 into Phase III Trials in the US
  • Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval
  • Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes
  • GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations
  • Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Xgene Pharmaceutical Secures $35M Series D Funding to Advance Non-Opioid Pain Therapy XG005 into Phase III Trials in the US

Company Drug

Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval

Company Drug

Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes

Company

GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.